Hanmi Fine Chemical's Transformation... Creating Innovative Growth Engine as a "High-Tech CDMO"

LNP and Peptide 'High-Difficulty New Drug' CDMO Challenge
100 Billion Won Scale Facility Investment Undertaken

Hanmi Precision Chemical.

[Asia Economy Reporter Lee Gwan-ju] Hanmi Precision Chemical, a raw material pharmaceutical company under Hanmi Pharmaceutical Group, is making a full-scale challenge into the contract development and manufacturing organization (CDMO) business. The company plans to create future growth engines by expanding beyond its existing main business area of raw material pharmaceuticals into the high-tech CDMO field, which involves complex new drugs.

Hanmi Precision Chemical announced on the 2nd that it will expand its business scope to the CDMO business in the high-difficulty synthetic biopharmaceutical field, including LNP (lipid nanoparticles) used in raw materials for mRNA vaccines, nucleotides, capping agents, polyethylene glycol (PEG) derivatives, and peptides.

To this end, Hanmi Precision Chemical is investing about 10 billion KRW to carry out facility expansion construction for the ‘high-tech CDMO’. Last year, the company was selected for the government’s COVID-19 vaccine and raw material production facility expansion project and received 1.6 billion KRW in support, and plans to upgrade its facilities by adding about 8 billion KRW of its own funds.

Hanmi Precision Chemical plans to secure global competitiveness in the CDMO field based on its accumulated know-how from participating in Hanmi Pharmaceutical’s bio and anticancer new drug research and development (R&D), as well as passing GMP inspections from major pharmaceutical advanced countries including the US FDA, Germany, the UK, and Japan.

Hanmi Precision Chemical is evaluated to have already established a mass production base for high-purity new drug raw materials through its experience participating in various new drug projects of Hanmi Pharmaceutical. Currently, it is responsible for the raw material development and production of Hanmi Pharmaceutical’s innovative new drugs Velpatasvir (partner Genentech), FLT3 (partner Aptose), and Poziotinib (partner Spectrum), and also develops and produces raw materials for Hanmi’s core biopharmaceuticals such as LAPSTriple Agonist, LAPSDual Agonist, LAPSGlucagon Analog, and LAPSGLP-2 Analog. Based on this, Hanmi Precision Chemical is conducting preclinical and clinical CDMO projects worth about 10 billion KRW with more than 10 domestic and overseas companies.

Jang Young-gil, CEO of Hanmi Precision Chemical, said, “Our capability to rapidly develop substances requiring complex synthetic technologies such as mRNA raw materials has already reached the highest level in Korea, and we have sufficient global competitiveness,” adding, “We expect that the ‘high-tech CDMO’, which will be promoted as a core business in the future, will greatly contribute to Hanmi Precision Chemical’s future growth.”

This content was produced with the assistance of AI translation services.